Cargando…

Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece

OBJECTIVES: We aimed to estimate the total mean annual treatment cost of different therapy options for patients with moderate-to-severe rheumatoid arthritis (RA) in Greece. METHODS: A cost-minimization approach was adopted. An economic model was developed to estimate the direct costs of the three wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragoulakis, Vasilis, Vitsou, Elli, Hernandez, Ana Cristina, Maniadakis, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303331/
https://www.ncbi.nlm.nih.gov/pubmed/25653545
http://dx.doi.org/10.2147/CEOR.S75323
_version_ 1782353930601103360
author Fragoulakis, Vasilis
Vitsou, Elli
Hernandez, Ana Cristina
Maniadakis, Nikolaos
author_facet Fragoulakis, Vasilis
Vitsou, Elli
Hernandez, Ana Cristina
Maniadakis, Nikolaos
author_sort Fragoulakis, Vasilis
collection PubMed
description OBJECTIVES: We aimed to estimate the total mean annual treatment cost of different therapy options for patients with moderate-to-severe rheumatoid arthritis (RA) in Greece. METHODS: A cost-minimization approach was adopted. An economic model was developed to estimate the direct costs of the three widely used treatments within a 1-year time horizon, from a health care payer perspective, either for new or for existing patients. Data on resource use, dose escalation, and frequency of therapy were based on a nationwide field survey of rheumatologists. Other analyses were also undertaken based on evidence from the literature. Total cost comprised the cost of drugs, administration, and hospital day care visits. Unit cost data were obtained from the price bulletin and the government gazettes issued by the Ministry of Health. Due to the short time horizon of the study, the cost was not discounted. RESULTS: The mean annual total cost per new (or per existing) responder patient on etanercept was estimated at €9,845 (€9,840), and the total cost on etanercept/methotrexate (MTX) was estimated at €9,857 (€9,852). Therapy with etanercept had lower annual cost relative to adalimumab and infliximab. On an annual basis, it was estimated that the difference between etanercept monotherapy and adalimumab monotherapy was €544 (€1,323). Similarly, the difference between etanercept/MTX and infliximab/MTX was €1,871 (€1,490) and €543 (€1,323), respectively, relative to adalimumab/MTX. Results remained constant under other scenario analyses undertaken. CONCLUSION: In the real-life practice setting in Greece, where dose intensity and frequency differences occur, etanercept alone or in combination with MTX, if prescribed as per label, represents the option with lower annual cost per patient when compared with adalimumab or infliximab in patients with RA. These results hold true as long as the assumptions and data used in the analysis remain stable and may alter if any of the underlying parameters, such as drug price, change.
format Online
Article
Text
id pubmed-4303331
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43033312015-02-04 Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece Fragoulakis, Vasilis Vitsou, Elli Hernandez, Ana Cristina Maniadakis, Nikolaos Clinicoecon Outcomes Res Original Research OBJECTIVES: We aimed to estimate the total mean annual treatment cost of different therapy options for patients with moderate-to-severe rheumatoid arthritis (RA) in Greece. METHODS: A cost-minimization approach was adopted. An economic model was developed to estimate the direct costs of the three widely used treatments within a 1-year time horizon, from a health care payer perspective, either for new or for existing patients. Data on resource use, dose escalation, and frequency of therapy were based on a nationwide field survey of rheumatologists. Other analyses were also undertaken based on evidence from the literature. Total cost comprised the cost of drugs, administration, and hospital day care visits. Unit cost data were obtained from the price bulletin and the government gazettes issued by the Ministry of Health. Due to the short time horizon of the study, the cost was not discounted. RESULTS: The mean annual total cost per new (or per existing) responder patient on etanercept was estimated at €9,845 (€9,840), and the total cost on etanercept/methotrexate (MTX) was estimated at €9,857 (€9,852). Therapy with etanercept had lower annual cost relative to adalimumab and infliximab. On an annual basis, it was estimated that the difference between etanercept monotherapy and adalimumab monotherapy was €544 (€1,323). Similarly, the difference between etanercept/MTX and infliximab/MTX was €1,871 (€1,490) and €543 (€1,323), respectively, relative to adalimumab/MTX. Results remained constant under other scenario analyses undertaken. CONCLUSION: In the real-life practice setting in Greece, where dose intensity and frequency differences occur, etanercept alone or in combination with MTX, if prescribed as per label, represents the option with lower annual cost per patient when compared with adalimumab or infliximab in patients with RA. These results hold true as long as the assumptions and data used in the analysis remain stable and may alter if any of the underlying parameters, such as drug price, change. Dove Medical Press 2015-01-16 /pmc/articles/PMC4303331/ /pubmed/25653545 http://dx.doi.org/10.2147/CEOR.S75323 Text en © 2015 Fragoulakis et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Fragoulakis, Vasilis
Vitsou, Elli
Hernandez, Ana Cristina
Maniadakis, Nikolaos
Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
title Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
title_full Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
title_fullStr Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
title_full_unstemmed Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
title_short Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
title_sort economic evaluation of anti-tnf agents for patients with rheumatoid arthritis in greece
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303331/
https://www.ncbi.nlm.nih.gov/pubmed/25653545
http://dx.doi.org/10.2147/CEOR.S75323
work_keys_str_mv AT fragoulakisvasilis economicevaluationofantitnfagentsforpatientswithrheumatoidarthritisingreece
AT vitsouelli economicevaluationofantitnfagentsforpatientswithrheumatoidarthritisingreece
AT hernandezanacristina economicevaluationofantitnfagentsforpatientswithrheumatoidarthritisingreece
AT maniadakisnikolaos economicevaluationofantitnfagentsforpatientswithrheumatoidarthritisingreece